Published on European Cystic Fibrosis Society (ECFS) (https://www.ecfs.eu)

Home > Studying the impact of rifabutin on elexacaftor/tezacaftor/ivacaftor (ETI) treatment in cystic fibrosis

Studying the impact of rifabutin on elexacaftor/tezacaftor/ivacaftor (ETI) treatment in cystic fibrosis

Resource Type

CF Research News

Authors

M Sanders, E Hong, P S Chung, A P Rao, W Cohn, P Beringer

References

J Cyst Fibros. 2025 Sep 15:S1569-1993(25)01581-4.  doi: 10.1016/j.jcf.2025.09.002

Document

File JCF-D-25-00209R1_FINAL_Beringer_01102025.docx [1]

Keywords

CYP3A4 induction [2]
Cystic fibrosis [3]
Drug-drug interactions [4]
ETI [5]
Pharmacokinetics [6]
Rifabutin [7]

Date

Monday, September 15, 2025

Featured resource article

Yes

Resource - Guideline Type

Other Guidelines [8]
Source URL:https://www.ecfs.eu/resource-article/cf-research-news/studying-impact-rifabutin-elexacaftortezacaftorivacaftor-eti

Links
[1] https://www.ecfs.eu/sites/default/files/cf-research-article-files/JCF-D-25-00209R1_FINAL_Beringer_01102025.docx [2] https://www.ecfs.eu/research-article-keywords/cyp3a4-induction [3] https://www.ecfs.eu/research-article-keywords/cystic-fibrosis [4] https://www.ecfs.eu/research-article-keywords/drug-drug-interactions [5] https://www.ecfs.eu/research-article-keywords/eti [6] https://www.ecfs.eu/research-article-keywords/pharmacokinetics [7] https://www.ecfs.eu/research-article-keywords/rifabutin [8] https://www.ecfs.eu/resource-guideline-type/other-guidelines